Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity ...
After being all-but written off a year ago, AstraZeneca’s anifrolumab has been reborn with new data that suggest it could help to end a drought in treatments for autoimmune disease systemic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback